Annovis Bio Inc expected to post a loss of 53 cents a share - Earnings Preview

Reuters11-04

* Annovis Bio Inc is expected to show no change in quarterly revenue when it reports results on November 6 (estimated) for the period ending January 1 0001

*

* LSEG's mean analyst estimate for Annovis Bio Inc is for a loss of 53 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts had fallen by about 26.1% in the last three months.

* Wall Street's median 12-month price target for Annovis Bio Inc is 26.00, above its last closing price of $9.09.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.69 -0.63 -0.32 Beat 49.2

Mar. 31 2024 -0.84 -0.80 -0.10 Beat 87.5

Dec. 31 2023 -1.39 -1.30 -2.24 Missed -71.7

Sep. 30 2023 -1.06 -1.09 -1.63 Missed -49.5

Jan. -1.11 -1.14 -1.07 Beat 6.3

1 0001

Jan. 1 0001 -0.33 -0.33 -1.19 Missed -256.3

Dec. 31 2022 -1.05 -1.05 -0.38 Beat 63.9

Sep. 30 2022 -1.02 -1.01 -0.93 Beat 8.2

This summary was machine generated November 4 at 15:47 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480158002?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 23:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480158002","market":"us","top_or_hot":-1,"title":"Annovis Bio Inc    expected to post a loss of 53 cents a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* Annovis Bio Inc     is expected to show no change in quarterly revenue when it reports  results on November 6 (estimated) for the period ending January 1 0001</p><p>   * </p><p>   * LSEG's mean analyst estimate for Annovis Bio Inc is for a loss of 53 cents per share. </p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts had fallen by about 26.1% in the last three months. </p><p>   * Wall Street's median 12-month price target for Annovis Bio Inc is 26.00, above its last closing price of $9.09. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Jun. 30 2024  -0.69       -0.63      -0.32     Beat    49.2</p><p>Mar. 31 2024  -0.84       -0.80      -0.10     Beat    87.5</p><p>Dec. 31 2023  -1.39       -1.30      -2.24     Missed  -71.7</p><p>Sep. 30 2023  -1.06       -1.09      -1.63     Missed  -49.5</p><p>Jan.        -1.11       -1.14      -1.07     Beat    6.3</p><p>1 0001                                                 </p><p>Jan. 1 0001   -0.33       -0.33      -1.19     Missed  -256.3</p><p>                                                       </p><p>Dec. 31 2022  -1.05       -1.05      -0.38     Beat    63.9</p><p>Sep. 30 2022  -1.02       -1.01      -0.93     Beat    8.2</p><p>This summary was machine generated November 4 at 15:47 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Annovis Bio Inc    expected to post a loss of 53 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnnovis Bio Inc    expected to post a loss of 53 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-04 23:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Annovis Bio Inc     is expected to show no change in quarterly revenue when it reports  results on November 6 (estimated) for the period ending January 1 0001   *    * LSEG's mean analyst estimate ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANVS","symbol_name":"Annovis Bio, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2480158002","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480158002","pubTimestamp":1730735301,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Annovis Bio Inc     is expected to show no change in quarterly revenue when it reports  results on November 6 (estimated) for the period ending January 1 0001   *    * LSEG's mean analyst estimate f","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ANVS":"Annovis Bio, Inc."},"translate_title":"Annovis Bio Inc预计每股亏损53美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANVS":1},"content_text":"* Annovis Bio Inc     is expected to show no change in quarterly revenue when it reports  results on November 6 (estimated) for the period ending January 1 0001   *    * LSEG's mean analyst estimate for Annovis Bio Inc is for a loss of 53 cents per share.    * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts had fallen by about 26.1% in the last three months.    * Wall Street's median 12-month price target for Annovis Bio Inc is 26.00, above its last closing price of $9.09. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  ESTIMATE             MET,    SE %              E®                               MISSED  Jun. 30 2024  -0.69       -0.63      -0.32     Beat    49.2Mar. 31 2024  -0.84       -0.80      -0.10     Beat    87.5Dec. 31 2023  -1.39       -1.30      -2.24     Missed  -71.7Sep. 30 2023  -1.06       -1.09      -1.63     Missed  -49.5Jan.        -1.11       -1.14      -1.07     Beat    6.31 0001                                                 Jan. 1 0001   -0.33       -0.33      -1.19     Missed  -256.3                                                       Dec. 31 2022  -1.05       -1.05      -0.38     Beat    63.9Sep. 30 2022  -1.02       -1.01      -0.93     Beat    8.2This summary was machine generated November 4 at 15:47 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480158002"}